Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Proactive Investors presentation, Sydney and Melbourne, February 2019
20 slides from Kazia Therapeutics's conference presentation, Feb 19, 2019
Slide 1: Presentation to Proactive Investors, Sydney & Melbourne
A company developing innovative, high-impact drugs for cancer Presentation to Proactive Investors Sydney, NSW & Melbourne, VIC 18 & 19 February 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Reasons to invest in Kazia
Multiple data read-outs from international human trials at world-class cancer hospitals are expected during calendar 2019, each with significant potential to generate additional investor and partnering interest Reasons to invest in Kazia We target a highly aggressive form of brain cancer, glioblasto
Slide 4: Glioblastoma is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung 14 million cancer cases per annum Breast Colon Prostate Stomach No clear cause or strong risk factors 3-4 months untreated survival 12-15 months average survival with treatment Any age, but most common in 60s
Slide 5: Treatment of GBM has improved little in recent decades, unlike other cancers
Treatment of GBM has improved little in recent decades, unlike other cancers Lung Cancer Glio-blastoma 1990s 1990s 2000s 2000s 2010s 2010s
Slide 6: Current treatment is essentially ineffective in approximately 65% of GBM cases
Current treatment is essentially ineffective in approximately 65% of GBM cases Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003 ~35% of patients respond to temozolomide Extends overall survival from 15 to 22 months ~65% of patients don’t respond to temozolomide Exten
Slide 7: GDC-0084 works by switching off a critical control mechanism that drives many cancers
GDC-0084 works by switching off a critical control mechanism that drives many types of cancer PI3K A central biochemical control mechanism in the growth of cells PI3K ACTIVATED PI3K INHIBITED TUMOUR GROWTH TUMOUR INHIBITION 85 – 90% of glioblastoma cases have PI3K ‘switched on’ GDC-0084 switches off
Slide 8: GDC-0084 is the only drug of its kind able to cross the blood-brain barrier
GDC-0084 is the only drug of its kind that is able to cross the ‘blood-brain barrier’ (BBB) Most drugs cannot reach disease in the brain GDC-0084 crosses the BBB The ‘blood-brain barrier’ prevents most drugs from getting into the brain, rendering them useless as treatments for brain cancer GDC-0084
Slide 9: Phase 1 trial of GDC-0084 showed favourable safety and multiple efficacy signals
A phase 1 human trial of GDC-0084 showed favourable safety and multiple efficacy signals * Taal et al., Lancet Oncology (2015): ORR and mPFS of Lomustine in 2L GBM were 2/41 (5%) and 1 months, respectively (n = 46) † Schwarzenberg J, et al. Clin Cancer Res; 20(13); 3550–9 Efficacy Signals Safety Pha
Slide 10: In the GDC-0084 phase 1 trial, 26% of patients showed a response to drug
In the GDC-0084 phase 1 trial, 7 / 27 patients (26%) showed a response to drug* * Metabolic partial response per FDG-PET Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084
Slide 11: Kazia has started a phase 2 study, and will report several data read-outs this year
Kazia has started a phase 2 study, and will report several data read-outs this year GDC-0084 Glioblastoma Multiforme (GBM) Cantrixil Ovarian Cancer Preliminary data from phase 1 study in ovarian cancer Completion of Part A of phase 1 study (safety and dosing)* *Full publication plans to be determine
Slide 12: Leading researchers are testing the drug in other forms of brain cancer
Aside from Kazia’s GBM study, leading researchers are testing the drug in other forms of brain cancer Note: All studies performed substantially in US under IND Preclinical Phase I Phase II Phase III GDC-0084 PI3K / mTOR Inhibitor Licensed from Genentech in October 2016 Breast Cancer Brain Metastases
Slide 13: These additional uses of the drug have the potential to significantly increase the commercial opportunity
These additional uses of the drug have the potential to significantly increase the commercial opportunity ~$1.5B+ market opportunity ~$3B+ market opportunity Other potential future indications INDICATIVE HER2+ Breast Cancer (Brain Metastases) Glioblastoma (most common brain cancer)
Slide 14: A second program, Cantrixil, is in a phase 1 study in ovarian cancer
A second program, Cantrixil, is currently in a phase 1 study in ovarian cancer, with data reporting this year Part A: Dose Escalation 3 to 42 patients in up to 8 cohorts Seeks to establish maximum tolerated dose and understand safety profile Part B: Dose Expansion 12 patients, all at 5 mg/kg Seeks t
Slide 15: Kazia is now well-funded to see its R&D programs through key data read-outs in 2019
Kazia is now well-funded to see its R&D programs through key data read-outs in calendar 2019 *NOX shares valued as at January 2019 $9.3M Current assets as at 30 June 2018 ~$2.5M* Shares in Noxopharm (ASX:NOX) $4.2M Proceeds from inst. placement & SPP in Oct 18 Current funding allows:- Completion of
Slide 16: Kazia is NASDAQ & ASX listed
Kazia is NASDAQ & ASX listed Market Capitalisation AU$ 26 million Shares on Issue 62 million (25% US, 75% Australia) Current Assets (Jun 18) US$ 6.9 million Listing NASDAQ: KZIA (1:10 ratio) ASX: KZA Share Price (AU$) Outstanding Options / Warrants ~6 million Average Daily Volume NASDAQ: 0.4% /day A
Slide 17: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Chairman Executive and Board roles in pharma and small biotech Bryce Carmine Deputy Chairman 36 years executive experience in Eli Lilly Steven Coffey Non-Executive Director C
Slide 18: Other companies focused on the PI3K pathway have been highly-valued in the market
Single asset company with one PI3K inhibitor in phase I human trials US$ 140 million Market Cap One PI3K inhibitor in phase II human trials, one other drug in phase III, and two in animal testing US$ 430 million Market Cap One PI3K inhibitor in phase II human trials Acquired by big pharma in 2011 fo
Slide 19: Reasons to invest in Kazia
Multiple data read-outs from international human trials at world-class cancer hospitals are expected during calendar 2019, each with significant potential to generate additional investor and partnering interest Reasons to invest in Kazia We target a highly aggressive form of brain cancer, glioblasto
Slide 20: www.kaziatherapeutics.com
www.kaziatherapeutics.com
Kazia Therapeutics — Proactive Investors presentation, Sydney and Melbourne, February 2019 on 6ix